药物输送的共同研究及授权契约:2019年～2025年

"药物输送领域的合作与授权协议" 提供了前所未有的途径，让我们能够全面了解世界领先生物製药公司达成的药物输送交易。

这份经过全面修订和更新的报告详细介绍了2019年至2025年的药物输送交易。

本报告详细解读并分析了企业达成药物输送交易的方式和原因。这些交易通常涉及多个环节，从合作研发开始，到成果商业化结束。

本报告涵盖了合作、开发、研究和授权交易。

本报告包​​含自2019年以来宣布的1,246项药物输送交易的完整列表，其中包括交易各方披露的实际药物输送合作交易的在线交易记录链接以及财务条款（如有）。此外，我们会尽可能记录公司及其合作伙伴向美国证券交易委员会提交的合约文件。

本报告第一章介绍了药物递送交易。

第一章是对报告的介绍。

第二章概述了自2019年以来的药物递送交易趋势。

第三章概述了自2019年以来具有代表性的药物递送交易。交易按总价值列出。

第四章提供了药物递送交易中最活跃的25家公司的综合列表，随后进行了简要摘要，并提供了公开的合约文件。

第五章对自2019年1月以来签署和宣布的药物递送交易进行了全面深入的回顾，这些交易的合约文件均可公开查阅。

第六章全面深入地回顾了自2019年1月以来达成和宣布的药物输送合作交易。本章以特定的药物传输技术类型进行组织。

报告还提供了大量图表和数据，显示了自2019年以来药物输送交易的趋势和活动。

此外，报告还提供了一个全面的交易目录，按公司A-Z、交易类型和治疗目标进行整理。每个交易标题都透过网页连结连结到线上交易记录，并包含合约文件（如有），方便您随时存取每个合约文件。

主要的优点

药物输送合作与授权协议为读者提供以下主要优势：

• 了解 2019 年及以后的交易趋势
• 浏览药物传递合作与授权协议
• 基准分析 - 确定交易的市场价值
• 财务条款 - 一次性付款、里程碑付款、特许权使用费
• 公司 A-Z、交易类型和治疗领域排列的交易目录
• 主要交易价值
• 最活跃的交易者
• 确定每笔交易的资产和交易条款
• 存取合约文件 - 深入了解交易结构
• 尽职调查 - 评估拟议交易条款是否适合您的合作伙伴
• 节省数百小时的研究时间

调查范围

• 药物输送合作与许可协议旨在深入了解药物输送全球领先生物製药公司签署的药物输送合作与许可协议包括：

药物输送合作与授权协议包括：

• 生物製药产业的药物输送交易趋势
• 涵盖製药和生物技术领域的药物传输交易记录目录
• 主要药物输送交易
• 最活跃的药物输送许可交易商
• 药物输送合作与许可协议提供全面的交易记录访问，包括可用的合约文件。

分析协议有助于进行以下的尽职调查：

• 授予或选择的具体权利是什么？
• 合约实际上授予合作公司什么？
• 授予了哪些独家权利？
• 合约的付款结构是怎样的？
• 如何审计销售额和付款？
• 合约期限是多久？
• 合约的关键条款是如何定义的？
• 知识产权如何处理与归属？
• 谁负责商业化？
• 谁负责开发、供应和製造？
• 如何管理保密和资讯揭露？
• 如何解决争议？
• 合约在什么情况下可以终止？
• 如果所有权发生变更会怎样？
• 双方约定了哪些再授权和分包条款？
• 公司坚持哪些标准条款？
• 哪些标准条款似乎因合作伙伴和交易类型而异？
• 公司在契约法方面主张哪些管辖权？

目录

摘要整理

第1章 简介

第2章 药物输送交易趋势

• 简介
• 多年的药物输送交易
• 最活跃的药物输送交易业者
• 药物输送交易，各交易类型
• 药物输送交易，各治疗领域
• 药物输送交易，各业界
• 药物输送交易的交易条件
  • 药物输送交易的标题金额
  • 药物输送契约的预付款
  • 药物输送契约的里程金
  • 药物输送权利金费率

第3章 -主要药物输送交易

• 简介
• 主要的药物输送交易，各金额

第4章 -最活跃的药物输送交易业者

• 简介
• 最活跃的药物输送交易业者
• 最活跃的药物输送交易的企业简介

第5章 -药物输送契约交易名录

• 简介
• 药物输送契约交易名录

第6章 -各技术类型的药物输送交易

• 交易名录
• 交易名录- 药物输送交易，各企业
• 交易名录- 药物输送交易，各交易类型
• 交易名录- 药物输送交易，各治疗领域
• 交易类型定义
• 关于调查公司
• 目前联盟
• 目前契约
• 最近的报告标题

Drug Delivery Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the drug delivery deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of drug delivery deals from 2019 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter drug delivery deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 1246 drug delivery deals announced since 2019 including financial terms where available including links to online deal records of actual drug delivery partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of drug delivery dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in drug delivery dealmaking since 2019.

Chapter 3 provides an overview of the leading drug delivery deals since 2019. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in drug delivery dealmaking with a brief summary followed by a comprehensive listing of drug delivery deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of drug delivery deals signed and announced since Jan 2019, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of drug delivery partnering deals signed and announced since Jan 2019. The chapter is organized by specific drug delivery technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in drug delivery deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Drug Delivery Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse drug delivery collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Drug Delivery Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of drug delivery trends and structure of deals entered into by leading biopharma companies worldwide.

Drug Delivery Collaboration and Licensing Deals includes:

• Trends in drug delivery dealmaking in the biopharma industry
• Directory of drug delivery deal records covering pharmaceutical and biotechnology
• The leading drug delivery deals by value
• Most active drug delivery licensing dealmakers
• Drug Delivery Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in drug delivery dealmaking

• 2.1. Introduction
• 2.2. Drug delivery deals over the years
• 2.3. Most active drug delivery dealmakers
• 2.4. Drug delivery deals by deal type
• 2.5. Drug delivery deals by therapy area
• 2.6. Drug delivery deals by industry sector
• 2.7. Deal terms for drug delivery deals
  • 2.7.1 Drug delivery deals headline values
  • 2.7.2 Drug delivery deal upfront payments
  • 2.7.3 Drug delivery deal milestone payments
  • 2.7.4 Drug delivery royalty rates

Chapter 3 - Leading drug delivery deals

• 3.1. Introduction
• 3.2. Top drug delivery deals by value

Chapter 4 - Most active drug delivery dealmakers

• 4.1. Introduction
• 4.2. Most active drug delivery dealmakers
• 4.3. Most active drug delivery deals company profiles

Chapter 5 - Drug delivery contracts dealmaking directory

• 5.1. Introduction
• 5.2. Drug delivery contracts dealmaking directory

Chapter 6 - Drug delivery dealmaking by technology type

• Deal directory
• Deal directory - Drug delivery deals by company A-Z
• Deal directory - Drug delivery deals by deal type
• Deal directory - Drug delivery deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Drug delivery deals since 2019
• Figure 2: Active drug delivery dealmaking activity - 2019 - 2025
• Figure 3: Drug delivery deals by deal type since 2019
• Figure 4: Drug delivery deals by therapy area since 2019
• Figure 5: Drug delivery deals by industry sector since 2019
• Figure 6: Drug delivery deals with a headline value
• Figure 7: Drug delivery deals with an upfront value
• Figure 8: Drug delivery deals with a milestone value
• Figure 9: Drug delivery deals with a royalty rate value
• Figure 10: Top drug delivery deals by value since 2019
• Figure 11: Most active drug delivery dealmakers 2019 - 2025
• Figure 12: Drug delivery deals by technology type since 2019